经导管主动脉瓣置换术:经股动脉、经颈动脉与经腔静脉途径的比较
本研究比较了本中心2015年1月至2017年3月间491例经导管主动脉瓣置换术患者中463例的经股动脉(373例)、经腔静脉(58例)和经颈动脉(32例)途径,发现三组30天/院内死亡率、出院回家比例、30天再入院率及1年生存率相似。
要点
- 经腔静脉组STS风险评分高于经股动脉组(8.0±5.2 vs 6.1±4.3,p=0.004)。
- 中位住院天数经股动脉2天、经颈动脉3天、经腔静脉4天(经股动脉 vs 经腔静脉,p=0.001)。
- 1年未校正Kaplan-Meier生存率经股动脉86%、经颈动脉83%、经腔静脉80%,三组相似。
核心结论
- 不适合经股动脉途径的患者接受经颈动脉或经腔静脉途径TAVR,其30天/院内及1年生存率与同期经股动脉途径队列相似。
- 避免经胸外科入口可能提供与经股动脉TAVR相当的手术和中短期结局。
研究设计与样本
- 本研究为单中心研究,2015年1月至2017年3月本机构共491例患者接受TAVR,其中463例纳入分析。
- 瓣膜输送途径:经股动脉373例,经腔静脉58例,经颈动脉32例。
- 比较患者特征和结局,包括1年生存率。
主要发现
- 经腔静脉组STS风险评分高于经股动脉组(8.0±5.2 vs 6.1±4.3,p=0.004)。
- 肺部疾病、脑血管疾病和外周血管疾病在经颈动脉和经腔静脉组更常见。
- 中位住院天数经股动脉2天、经颈动脉3天、经腔静脉4天(经股动脉 vs 经腔静脉,p=0.001)。
- 手术死亡率、出院回家比例和30天再入院率三组相似。
- 1年未校正Kaplan-Meier生存率相似(经股动脉86%,经颈动脉83%,经腔静脉80%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite newer-generation valves using smaller-sized sheaths, 10% to 20% of patients undergoing transcatheter aortic valve replacement (TAVR) require nonfemoral artery access for valve delivery. To avoid a transthoracic procedure, we have used transcarotid (TC) and transcaval (TCav) approaches in these patients. This study compared the results of a contemporary experience with transfemoral (TF), TC, and TCav approaches. METHODS: Between January 2015 and March 2017, 491 patients underwent TAVR at our institution, of which 463 were included in this analysis. Valve delivery was TF in 373 patients, TCav in 58, and TC in 32. Patient characteristics and outcomes, including 1-year survival, were compared. RESULTS: Preoperative demographics and postoperative outcomes were similar for the three groups with several exceptions. TCav patients had higher The Society of Thoracic Surgeons risk score than TF patients (8.0 ± 5.2 vs 6.1 ± 4.3, p = 0.004). Lung disease, cerebrovascular disease, and peripheral vascular disease were more common in TC and TCav patients. Median length of stay was 2 days for TF, 3 days for TC, and 4 days for TCav (TF vs TCav, p = 0.001). Procedural mortality, percentage discharged home, and the 30-day readmission rate were similar for all. Unadjusted Kaplan-Meier survival was also similar at 1 year (TF, 86%; TC, 83%; TCav, 80%). CONCLUSIONS: Patients unsuitable for TF TAVR treated with TC or TCav access had 30-day/in-hospital and 1-year survival similar to a contemporary cohort undergoing TF access. Avoiding surgical entry to the chest may offer procedural and intermediate-term outcomes equivalent to TF TAVR.
引用
- Paone G, Eng M, Kabbani LS, et al. Transcatheter Aortic Valve Replacement: Comparing Transfemoral, Transcarotid, and Transcaval Access. Ann Thorac Surg. 2018. PMID: 29758214. doi:10.1016/j.athoracsur.2018.04.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。